President Donald Trump signed an executive order Saturday[1] to accelerate federal review of psychedelic drugs, including the controversial ibogaine.
The move could reshape drug policy—an area long debated by clinicians and lawmakers. Accelerating research may expand treatment options for veterans suffering from post‑traumatic stress disorder and for patients with substance‑use disorders, while also prompting a safety review of substances that remain federally prohibited.
The order directs the Food and Drug Administration, the Drug Enforcement Administration and the National Institutes of Health to prioritize studies on efficacy, dosing and long‑term effects. It also instructs the agencies to examine the current Schedule I classification of psychedelics and to consider re‑scheduling if scientific evidence supports broader medical use.
Ibogaine, derived from an African shrub, has been used experimentally to interrupt opioid dependence, but it remains illegal under U.S. law. Proponents cite anecdotal success stories, while critics point to reports of cardiac complications and a lack of large‑scale clinical trials.
Medical organizations welcomed the expedited focus but cautioned that speed must not replace rigor. The American Psychiatric Association said the order "offers an opportunity to gather high‑quality data," while the Center for Drug Evaluation said that any approval pathway must retain thorough safety assessments.
The decision marks a shift from the previous administration, which placed a moratorium on federally funded psychedelic research. Trump’s action reflects growing bipartisan interest in alternative therapies, as several states have already de‑criminalized or legalized certain psychedelics for therapeutic use.
Implementation will begin within weeks, with agencies expected to issue detailed guidance by the end of the year. Researchers anticipate a surge in grant applications, and pharmaceutical firms have signaled interest in developing regulated ibogaine‑based medications.
“The order aims to fast‑track research into psychedelics for PTSD.”
By directing key federal agencies to prioritize psychedelic research, the administration could accelerate the development of new therapies for mental‑health conditions, but the expedited timeline also raises concerns about ensuring safety and scientific rigor before any drugs become widely available.
